Tuberculosis :: People potentially exposed to patient with extensively drug-resistant TB
The TB traveler is currently in isolation at an Atlanta hospital, and he’s under the care of infectious disease specialists at this hospital.
The TB traveler is currently in isolation at an Atlanta hospital, and he’s under the care of infectious disease specialists at this hospital.
US Presidential candidate and Sen. Barack Obama, in Iowa City, announced a proposal that would expand health insurance to almost all U.S. residents and reduce premium costs.
The $1 million, two-month project is a collaboration of 454 Life Sciences and the BCM Human Genome Sequencing Center (HGSC), said Dr. Richard Gibbs, director of the HGSC and a scientific advisor to the Connecticut-based company.
Rats paralyzed due to loss of blood flow to the spine returned to near normal ambulatory function six weeks after receiving grafts of human spinal stem cells (hSSCs), researchers from the University of California, San Diego (UCSD) School of Medicine report.
A new report in the June 1 issue of the journal Cell, a publication of Cell Press, confirms the existence of some apparently uncommitted stem cells amongst cells responsible for generating the bulging biceps of body builders and the rippling abs of fitness buffs.
An international team of researchers have been awarded more than ?2 million to study the genetic causes of dwarfism in a bid to develop future treatments.
Dey, L.P. announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) of its marketing partner, Critical Therapeutics, Inc. (Nasdaq: CRTX), for ZYFLO CR? (zileuton) extended-release tablets.
New findings show that the majority of people untrained in how to perform cardiopulmonary resuscitation, and even many trained emergency personnel, do not push with enough force to properly administer CPR.
Mass-media advertising can encourage more people experiencing stroke symptoms to go to the hospital more quickly, according to a study published in Stroke: Journal of the American Heart Association.
Vical Incorporated (Nasdaq:VICL) today announced that a measles DNA vaccine formulated with the company’s Vaxfectin? adjuvant elicited protective levels of neutralizing antibodies in juvenile (1 ? 2 year old) nonhuman primates confirmed by complete protection following challenge more than one year after vaccination, and sterilizing immunity as evidenced by no clinical signs of disease and no detectable virus after challenge.